Our Portfolio
Medical Devices
Bypass Solutions
A medtech startup developing an innovative percutaneous procedure to perform a suture-less bypass to treat long Ilio-femoral occlusions, offering an alternative to open surgical bypass.
Cagent Vascular, LLC
Cagent Vascular is a medical device company dedicated to improving the treatment of atherosclerotic cardiovascular disease, the leading cause of mortality and poor quality of life worldwide. This disease is caused by plaque accumulation inside arteries throughout the body resulting in diminished circulation. The company’s vision is to be the leader for treating atherosclerotic disease with the first and only serration balloon technology to restore blood flow. Our first products will treat diseased leg arteries, which if left untreated can lead to pain while walking, tissue loss, gangrene, and amputation.
CorWave
CorWave’s ambition is to create a new standard of care for a large spectrum of heart failure patients by introducing breakthrough implantable circulatory support solutions that restore a normal life with minimal side effects. At the core of the CorWave products, CorWave LVAD and CorWave Nemo, is a disruptive and patented pumping technology: the wave membrane. The membrane is the result of more than twenty years of research and development, and is capable of mimicking the native heart. The disruptive technology radically differentiates CorWave products from commercially-available rotary pump LVADs, and allows CorWave LVAD and CorWave Nemo to provide unique physiological blood flow.
LimFlow SA.
A minimally-invasive procedure, the LimFlow Percutaneous Deep Vein Arterilization (pDVA) System is designed to bypass blocked arteries in the leg and rush blood back into the foot, avoiding amputation, often resolving pain immediately and promoting wound healing.
Mercator MedSystems, INC
A medical technology company which is focused on the treatment of peripheral artery disease using its catheter-guided, micro-infusion systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel.
Pedra Technology
Pedra Technology is capable of accurately diagnosing patients at high risk of chronic and diabetic foot ulcers. The technology monitors vascular disease progression and triage between ischemic and neuropathic diabetic foot ulcers. It is the first technology in the market, to accurately track foot tissue perfusion in real-time during peripheral vascular procedures. Our mission is to reduce amputation of diabetic and ischemic limbs by driving our perfusion monitoring into multiple points of care in the diagnosis, treatment and monitoring of chronic foot ischaemia.
PICS Therapeutics
A pioneering company developing a novel approach to supporting patients with acute heart failure. For example, this can occur during acute heart attack and the device is designed to be quickly and easily placed to support cardiovascular function during the first few days of treatment and recovery.
This approach provides a highly effective mechanism for supporting both the heart and the kidneys with minimal blood damage, and avoids the potential for brain injury, problems experienced with other support devices. The PICS novel device uses nano engineering solutions to make it efficient and reliable, and uniqueness of location in the body which makes implant easy.
R3 Vascular
R3 Vascular has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of PAD below the knee. The R3 Vascular platform combines the best of both worlds of below-the-knee (BTK) therapy, designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals.
TISSIUM
Founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. With a unique approach to product development that leverages the knowledge gained from the development of their technology platform comprised of proprietary polymers, activation technologies, and delivery devices. TISSIUM has developed a fully integrated innovation, design, commercialisation and manufacturing platform to support their internal programs as well as co-development partnerships with leaders in the medtech industry.
UroDev Medical
A seed stage, venture-backed, medical device company developing products to improve the lives of patients with Spinal Cord Injury. The company has developed the Connected Catheter, the first fully internal, smart catheter system for adult males with Urinary Retention. The Connected Catheter is currently in a multi-centre study across the United States.
Xeltis
A medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels and valves. Xeltis’ devices seek to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an a within and around it, before gradually being absorbed and leaving new, living and long-lasting vessels and valves in place.
Funds
Sofinnova Partners
A leading European venture capital firm specialized in Life Sciences. The firm has over €2 billion under management through several funds.
Sofinnova Crossover I is a $300 million healthcare late stage fund focusing primarily on therapeutic and game-changing companies driven by experienced management.
MD Start III
A $50 million medtech acceleration fund.